고객사 설치제품 등록 양식입니다.
Sartorius_의약품 등 시험검사기관
자료 다운로드를 위해서는 고객정보사항 입력 및 Sartorius 뉴스레터 구독 동의가 필요합니다. 또한 브라우저(인터넷 익스플로러, 크롬 등) 팝업차단 옵션의 해제가 필요합니다.
요청하시는 제품과 고객정보를 자세히 입력해주시기 바랍니다. 빠른 시일내에 담당자가 연락드리도록 하겠습니다.
요청하시는 제품과 고객정보를 자세히 입력해주시기 바랍니다. 빠른 시일내에 담당자가 연락 드리도록 하겠습니다. 문의 제출이 되지 않는 경우 하기 필수 항목을 기재하여 (service@sartorius.co.kr) 로 메일 부탁 드립니다. (문의전화 Tel. 1600-0288 싸토리우스 서비스센터)
❌
고객사 설치제품 등록 양식입니다
![[포스터] Part 2 – Regulatory Considerations](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e44732ed69c4447483-120x90.jpg)
![[포스터] Part 2 – Regulatory Considerations](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e44732ed69c4447483-96x70.jpg)
![[포스터] Part 1 – The Need for Speed and Safety](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e446ec644156973058-120x90.jpg)
![[포스터] Part 1 – The Need for Speed and Safety](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e446ec644156973058-96x70.jpg)
![[White Paper] Can mRNA Disrupt The Biopharma Industry?](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e4468bb853f6865142-120x90.jpg)
![[White Paper] Can mRNA Disrupt The Biopharma Industry?](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e4468bb853f6865142-96x70.jpg)
![[어플리케이션 노트] Control and scale-up of a microcarrier-based viral vaccine process using BioPAT ® ViaMass for inline viable cell de](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e44647edd775263498-120x90.jpg)
![[어플리케이션 노트] Control and scale-up of a microcarrier-based viral vaccine process using BioPAT ® ViaMass for inline viable cell de](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e44647edd775263498-96x70.jpg)
![[브로셔] Accelerated Development, Manufacturing and Monitoring of Viral Vectors](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e44609c46dc9012584-120x90.jpg)
![[브로셔] Accelerated Development, Manufacturing and Monitoring of Viral Vectors](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e44609c46dc9012584-96x70.jpg)
![[브로셔] ABL Europe’s GMP manufacturing facility for viral vector production](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e445b63b59b1712301-120x90.jpg)
![[브로셔] ABL Europe’s GMP manufacturing facility for viral vector production](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e445b63b59b1712301-96x70.jpg)
![[포스터] Adenovirus Downstream Process Intensification](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e4456e774827923705-120x90.jpg)
![[포스터] Adenovirus Downstream Process Intensification](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e4456e774827923705-96x70.jpg)
![[포스터] Enabling Viral Vaccine Production](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e445299645f2858623-120x90.jpg)
![[포스터] Enabling Viral Vaccine Production](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e445299645f2858623-96x70.jpg)
![[포스터] Rapid Total Particle Quantification for Viral Families With High Potential for Pathogenic Emergence](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e444e283c319322506-120x90.jpg)
![[포스터] Rapid Total Particle Quantification for Viral Families With High Potential for Pathogenic Emergence](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e444e283c319322506-96x70.jpg)
![[브로셔] virus clearance charles rivers ruppach data](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e4448e28b1d5420286-120x90.jpg)
![[브로셔] virus clearance charles rivers ruppach data](https://www.sartorius.co.kr/wp-content/uploads/kboard_thumbnails/6/202107/60e4448e28b1d5420286-96x70.jpg)
